Abstract
Outpatient complications for fungal infections in immunocompromised patients and the development of antimicrobial drug resistance mechanisms demonstrate the need to develop new antifungal agents. In this perspective, heterocyclic compounds namely thiazolylhydrazones, furan, tetrazole, triazole and thiadiazoline derivatives were synthesized and tested in vitro against seven clinical importance Cryptococcus and Candida species. In this study, virtual screening techniques were applied using a scaffold-hopping database, FDA approved drugs and a ZINC subset. Some of the compounds evaluated showed promising antifungal activity against C. albicans, C. glabrata, C. krusei, C. parapsilosis, C. tropicalis, C. neoformans and C. gatti, displaying minimal inhibitory concentration (MIC) values in the range of 0.12–250 µM.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
